What is PetMed Express, Inc.'s earnings per share (EPS)?

PetMed Express, Inc. (PETS) reported diluted earnings per share of -$2.74 for fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

PetMed Express (PETS) Financials

PETS NASDAQ

Trailing 12 months to June 30, 2026

Revenue $168.9M -20.3% YoY

Net Income -$29.3M n/m YoY

EPS (Diluted) -$1.38 n/m YoY

Free Cash Flow -$27.8M n/m YoY

Market Cap $25.6M as of Oct 27, 2026

Price / Sales 0.2x on $168.9M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 1.1x on $23.0M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PETS SEC filings page.

PetMed Express, Inc. (PETS) reported $168.9M in revenue over the twelve months to Jun 30, 2026, down 20.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PETS FY2026 2026-10-25

The business has shifted from profitable operations and dividends to shrinking sales, cash consumption, and materially weaker balance-sheet capacity.

Revenue fell 21.1% in FY2026 while SG&A rose 31.3%; with gross margin still 28.1%, operating margin reached -32.8%. The collapse therefore sits below gross profit: overhead did not contract with demand, rather than merchandise economics alone explaining the loss.

Cash generation changed character: operating cash flow went from $4.7M in FY2025 to -$28.4M in FY2026. Free cash flow was -$33.0M despite positive gross profit, so the latest loss reflects operating strain rather than only non-cash charges.

Liabilities now represent 64.4% of assets, versus 42.7% in FY2025. A current ratio of 0.8x means current obligations exceeded current assets, while the reported liquidity comparison was 9 months of annual outflow.

Financial Health Signals

Financial Health Score (4 of 6 dimensions) 41/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of PetMed Express, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

PetMed Express, Inc. held $21.4M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $28.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and PetMed Express, Inc. scores 30/100 among other emerging companies.

Dilution

PetMed Express, Inc. had 21M shares outstanding at the end of fiscal year 2026, against 21M in fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and PetMed Express, Inc. scores 71/100 among other emerging companies.

R&D Intensity

n/a

Not available for PetMed Express, Inc., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.

Revenue Progress

PetMed Express, Inc. reported revenue of $179.0M in fiscal year 2026, against $227.0M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and PetMed Express, Inc. scores 21/100 among other emerging companies.

Burn Trend

n/a

Not available for PetMed Express, Inc., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.

Balance Sheet

PetMed Express, Inc.'s cash, cash equivalents and investments came to $21.4M at the end of fiscal year 2026, against $52.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and PetMed Express, Inc. scores 41/100 among other emerging companies.

Altman Z-Score Distress

0.15

PetMed Express, Inc. scores 0.15, below the 1.81 distress threshold. The score is pulled down most by an operating loss of $58.7M against total assets of $81.2M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

PetMed Express, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing

N/A

PetMed Express, Inc. reported a net loss of $57.3M while operations used $28.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$41.0M

YoY-19.9%

QoQ-4.2%

5Y CAGR-12.2%

10Y CAGR-5.5%

PetMed Express, Inc. generated $41.0M in revenue in Q1 2027. This represents a decrease of 19.9% from the same quarter a year earlier. Against the prior quarter it is down 4.2%.

EBITDA

-$4.1M

YoYn/m

QoQn/m

PetMed Express, Inc.'s EBITDA was -$4.1M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income

-$6.1M

YoYn/m

QoQn/m

PetMed Express, Inc. reported a net loss of $6.1M in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

-$0.28

YoYn/m

QoQn/m

PetMed Express, Inc. earned -$0.28 per diluted share (EPS) in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow

-$8.3M

YoYn/m

QoQn/m

5Y CAGRn/m

PetMed Express, Inc. recorded an outflow of $8.3M in free cash flow in Q1 2027, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt

$13.1M

YoY-68.2%

QoQ-38.9%

5Y CAGR-34.9%

10Y CAGR-11.5%

PetMed Express, Inc. held $13.1M in cash as of Q1 2027; no long-term debt figure is on record for that period.

Shares Outstanding

22M

YoY+3.2%

QoQ+1.5%

5Y CAGR+1.3%

10Y CAGR+0.5%

PetMed Express, Inc. had 22M shares outstanding in Q1 2027. This represents an increase of 3.2% from the same quarter a year earlier. Against the prior quarter it is up 1.5%.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Gross Margin

27.6%

YoY-0.5pp

QoQ-4.9pp

5Y change0.0pp

10Y change-3.3pp

PetMed Express, Inc.'s gross margin was 27.6% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.9 percentage points.

Operating Margin

-15.2%

YoY+51.5pp

QoQ-1.9pp

5Y change-22.1pp

10Y change-29.5pp

PetMed Express, Inc.'s operating margin was -15.2% in Q1 2027, reflecting core business profitability. This is up 51.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.

Net Margin

-15.0%

YoY+51.8pp

QoQ-5.5pp

5Y change-19.5pp

10Y change-24.1pp

PetMed Express, Inc.'s net profit margin was -15.0% in Q1 2027, showing the share of revenue converted to profit. This is up 51.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.5 percentage points.

Return on Equity

-26.7%

YoY+39.5pp

QoQ-12.7pp

5Y change-29.3pp

10Y change-34.4pp

PetMed Express, Inc.'s quarterly ROE was -26.7% in Q1 2027: one quarter's net income over shareholder equity, not annualized. This is up 39.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 12.7 percentage points.

Capital Allocation

Capital Expenditures

$641K

YoY-50.4%

QoQ-11.0%

5Y CAGR+6.1%

10Y CAGR-13.1%

PetMed Express, Inc. invested $641K in capex in Q1 2027, funding long-term assets and infrastructure. This represents a decrease of 50.4% from the same quarter a year earlier. Against the prior quarter it is down 11.0%.

R&D Spending

Not reported for Q1 2027.

Share Buybacks

Not reported for Q1 2027.

PETS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PETS quarterly income statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$168.9M	$179.0M-21.1%	$227.0M-17.2%	$274.1M+10.7%	$247.6M-9.1%	$272.3M-10.3%	$303.6M+6.8%	$284.1M+0.2%	$283.4M+3.5%	$273.8M+9.9%	$249.2M+6.2%	$234.7M+2.3%	$229.4M-1.7%	$233.4M+2.4%	$227.8M-4.4%	$238.3M
Cost of Revenue	N/A	N/A	$157.8M-16.6%	$189.3M+10.7%	$171.1M-12.4%	$195.3M-10.9%	$219.3M+8.1%	$202.9M+7.9%	$188.1M+6.9%	$176.0M+3.6%	$169.9M+7.2%	$158.4M+3.4%	$153.1M-1.7%	$155.8M+3.4%	$150.7M-4.7%	$158.1M
Gross Profit	$47.1M	$50.2M-27.4%	$69.1M-18.4%	$84.8M+10.8%	$76.5M-0.6%	$76.9M-8.7%	$84.3M+3.8%	$81.2M-14.8%	$95.3M-2.5%	$97.8M+23.3%	$79.3M+4.0%	$76.3M0.0%	$76.3M-1.7%	$77.6M+0.6%	$77.1M-3.8%	$80.2M
SG&A Expenses	$49.0M	$50.7M+31.3%	$38.6M-30.0%	$55.2M+32.4%	$41.7M+34.1%	$31.1M+4.7%	$29.7M+17.6%	$25.3M+2.0%	$24.8M+2.0%	$24.3M+6.5%	$22.8M+7.0%	$21.3M+0.9%	$21.1M-1.2%	$21.4M-1.1%	$21.6M-3.4%	$22.4M
Operating Income	-$30.8M	-$58.7Mn/m	-$1.5Mn/m	-$8.2M-234.9%	$6.1M-75.1%	$24.3M-20.4%	$30.5M-1.4%	$31.0M-32.9%	$46.2M-11.4%	$52.1M+39.1%	$37.5M+15.7%	$32.4M+17.3%	$27.6M-2.1%	$28.2M+4.5%	$27.0M+3.8%	$26.0M
EBITDA	N/A	-$49.3M-994.6%	$5.5Mn/m	-$1.1M-111.5%	$9.6M-64.5%	$27.0M-18.0%	$33.0M-0.8%	$33.2M-31.3%	$48.4M-10.8%	$54.3M+39.7%	$38.9M+17.2%	$33.2M+17.3%	$28.3M-2.8%	$29.1M+3.5%	$28.1M+2.4%	$27.4M
Income Tax	-$69K	-$73K-101.3%	$5.7M+377.2%	$1.2M-48.3%	$2.3M-57.9%	$5.5M-22.2%	$7.0M-12.6%	$8.0M-29.3%	$11.4M-31.0%	$16.5M+17.0%	$14.1M+17.5%	$12.0M+16.0%	$10.3M-0.8%	$10.4M+2.8%	$10.1M+4.4%	$9.7M
Net Income	-$29.3M	-$57.3Mn/m	-$6.3Mn/m	-$7.5M-245.2%	$5.1M-72.5%	$18.7M-21.8%	$23.9M-7.5%	$25.9M-31.5%	$37.7M+1.2%	$37.3M+56.5%	$23.8M+15.8%	$20.6M+17.8%	$17.5M-2.9%	$18.0M+4.7%	$17.2M+3.0%	$16.7M
EPS (Basic)	N/A	-$2.74n/m	-$0.30n/m	-$0.37-248.0%	$0.25-73.1%	$0.93-21.8%	$1.19-7.8%	$1.29-29.9%	$1.84+0.5%	$1.83+55.1%	$1.18+15.7%	$1.02+17.2%	$0.87	$0.90	$0.86+6.2%	$0.81
EPS (Diluted)	-$1.38	-$2.74n/m	-$0.30n/m	-$0.37-248.0%	$0.25-72.8%	$0.92-22.7%	$1.19-7.8%	$1.29-29.9%	$1.84+1.1%	$1.82+55.6%	$1.17+14.7%	$1.02+17.2%	$0.87	$0.90	$0.86+7.5%	$0.80
Diluted Shares (Avg)	N/A	21M+1.6%	21M+1.0%	20M+0.3%	20M-0.1%	20M+1.2%	20M+0.3%	20M-2.1%	20M+0.3%	20M+0.3%	20M+0.6%	20M+0.6%	20M	20,043	20M-3.2%	21M

Metric	Q1'2710-Q	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$41.0M-19.9%	$42.8M-15.6%	$40.7M-21.7%	$44.4M-23.6%	$51.2M-22.7%	$50.8M-22.0%	$52.0M-18.4%	$58.0M-16.4%
Cost of Revenue	$29.7M-19.3%	N/A	N/A	$31.9M-18.6%	$36.8M-22.0%	$35.6M-22.6%	$35.8M-19.0%	$39.3M-18.5%
Gross Profit	$11.3M-21.3%	$13.9M-8.3%	$9.5M-41.4%	$12.4M-33.9%	$14.4M-24.3%	$15.2M-20.4%	$16.1M-17.0%	$18.8M-11.7%
SG&A Expenses	$11.2M-13.5%	$11.4M-8.6%	$12.2M+13.1%	$14.2M+35.1%	$12.9M+165.7%	$12.5M-11.7%	$10.8M-19.7%	$10.5M-12.3%
Operating Income	-$6.2Mn/m	-$5.7Mn/m	-$10.5Mn/m	-$8.4M-1612.6%	-$34.1M-878.2%	-$6.0Mn/m	-$450Kn/m	$554K-36.7%
EBITDA	-$4.1Mn/m	-$3.3Mn/m	-$8.1M-810.4%	-$6.1M-375.9%	-$31.8M-621.5%	-$3.9Mn/m	$1.1Mn/m	$2.2M-14.5%
Interest Expense	$400K-20.0%	N/A	$400K0.0%	$326K	$500K	N/A	$400K	N/A
Income Tax	$13K+44.4%	-$102K-101.8%	$11K-97.6%	$9Kn/m	$9K-99.1%	$5.7M+268.6%	$465Kn/m	-$1.4M-348.0%
Net Income	-$6.1Mn/m	-$4.1Mn/m	-$10.6Mn/m	-$8.5M-466.3%	-$34.2M-1009.7%	-$11.6Mn/m	-$707Kn/m	$2.3M+225.3%
EPS (Basic)	-$0.28n/m	-$0.19n/m	-$0.50n/m	-$0.41-472.7%	-$1.65-1016.7%	-$0.56n/m	-$0.03n/m	$0.11+175.0%
EPS (Diluted)	-$0.28n/m	-$0.19n/m	-$0.50n/m	-$0.41-472.7%	-$1.65-1016.7%	-$0.56n/m	-$0.03n/m	$0.11+266.7%
Diluted Shares (Avg)	22M+4.5%	N/A	21M+1.8%	21M-0.2%	21M-0.9%	N/A	21M+1.0%	21M+0.8%

Not reported in any period shown, so not listed: R&D Expenses.

PETS Balance Sheet

PETS quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$81.2M-45.4%	$148.7M-12.5%	$169.9M+1.4%	$167.5M-6.8%	$179.7M-4.2%	$187.5M+20.7%	$155.3M+0.6%	$154.4M+14.5%	$134.8M+19.5%	$112.8M+25.0%	$90.3M+9.0%	$82.9M+5.7%	$78.4M+7.1%	$73.2M-19.6%	$91.1M
Current Assets	$43.6M-44.8%	$78.9M-15.8%	$93.6M-28.2%	$130.4M-13.6%	$151.0M-6.3%	$161.2M+24.9%	$129.0M+2.0%	$126.4M+20.1%	$105.2M+28.7%	$81.8M+20.9%	$67.6M-15.0%	$79.6M+7.2%	$74.2M+7.9%	$68.8M-21.5%	$87.6M
Cash & Equivalents	$21.4M-60.9%	$54.7M-1.0%	$55.3M-46.9%	$104.1M-6.3%	$111.1M-6.4%	$118.7M+14.4%	$103.8M+3.2%	$100.5M+29.0%	$77.9M+32.7%	$58.7M+56.0%	$37.6M+5.7%	$35.6M+94.6%	$18.3M+0.8%	$18.2M-61.2%	$46.8M
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$15.6M+0.3%	$15.5M+0.3%	$15.5M+49.7%	$10.3M
Inventory	$13.6M-16.0%	$16.2M-43.3%	$28.6M+50.1%	$19.0M-41.4%	$32.5M-5.7%	$34.4M+92.5%	$17.9M-16.3%	$21.4M-8.4%	$23.3M+15.4%	$20.2M-20.9%	$25.6M+2.1%	$25.1M-29.8%	$35.7M+13.1%	$31.6M+20.5%	$26.2M
Accounts Receivable	$1.9M-17.7%	$2.3M-29.4%	$3.3M+88.7%	$1.7M-9.0%	$1.9M-26.1%	$2.6M-32.7%	$3.8M+51.2%	$2.5M+10.9%	$2.3M+26.8%	$1.8M+4.9%	$1.7M-10.7%	$1.9M+9.7%	$1.8M+22.4%	$1.4M-8.5%	$1.6M
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	$0-100.0%	$26.7M0.0%	$26.7Mn/m	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$52.3M-17.8%	$63.6M-13.1%	$73.2M+27.2%	$57.5M+2.2%	$56.2M+21.7%	$46.2M+82.6%	$25.3M+28.2%	$19.7M+3.4%	$19.1M-1.7%	$19.4M+174.5%	$7.1M-4.5%	$7.4M-9.1%	$8.2M-11.0%	$9.2M-7.3%	$9.9M
Current Liabilities	$52.0M-17.1%	$62.8M-13.0%	$72.2M+25.5%	$57.5M+2.2%	$56.2M+25.2%	$44.9M+84.6%	$24.3M+30.7%	$18.6M+2.9%	$18.1M-1.3%	$18.4M+159.1%	$7.1M-4.5%	$7.4M-8.4%	$8.1M-10.0%	$9.0M-4.2%	$9.4M
Non-Current Liabilities	$217K-72.8%	$798K-19.8%	$995Kn/m	$0n/m	$0-100.0%	$1.3M+32.1%	$970K-13.5%	$1.1M+12.6%	$996K-8.5%	$1.1Mn/m	$0n/m	$0-100.0%	$65K-61.3%	$168K-65.9%	$492K
Total Equity	$28.9M-66.0%	$85.1M-12.0%	$96.7M-12.0%	$110.0M-10.9%	$123.5M-1.2%	$124.9M+3.8%	$120.3M-10.6%	$134.7M+16.4%	$115.7M+24.0%	$93.4M+12.2%	$83.2M+10.3%	$75.4M+7.4%	$70.2M+9.7%	$64.0M-21.1%	$81.2M
Retained Earnings	$9.3M-86.1%	$66.5M-7.0%	$71.6M-21.9%	$91.7M-18.0%	$111.8M-16.7%	$134.1M+6.3%	$126.2M+3.3%	$122.2M+14.9%	$106.3M+22.9%	$86.5M+10.5%	$78.3M+8.2%	$72.3M+5.4%	$68.6M+7.3%	$64.0M-21.1%	$81.1M

Metric	Q1'2710-Q	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$63.8M-41.9%	$81.2M-45.4%	$88.0M-39.2%	$100.3M-31.3%	$109.8M-28.1%	$148.7M-12.5%	$144.8M-16.5%	$146.0M-10.2%
Current Assets	$27.6M-59.3%	$43.6M-44.8%	$48.5M-29.1%	$59.5M-16.0%	$67.9M-12.5%	$78.9M-15.8%	$68.4M-28.4%	$70.8M-16.4%
Cash & Equivalents	$13.1M-68.2%	$21.4M-60.9%	$26.9M-46.3%	$36.1M-30.6%	$41.1M-10.6%	$54.7M-1.0%	$50.1M+1.3%	$52.0M-2.7%
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Inventory	$8.5M-53.9%	$13.6M-16.0%	$12.2M+3.5%	$14.8M+12.8%	$18.4M-28.1%	$16.2M-43.3%	$11.8M-65.9%	$13.1M-30.7%
Accounts Receivable	$1.7M+6.3%	$1.9M-17.7%	$1.6M-31.0%	$2.0M+21.3%	$1.6M-29.0%	$2.3M-29.4%	$2.3M+17.0%	$1.6M-25.5%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Goodwill	N/A	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$26.7M0.0%	$26.7M0.0%	$26.7M0.0%
Total Liabilities	$40.8M-30.1%	$52.3M-17.8%	$55.2M+13.6%	$57.2M+15.4%	$58.3M-1.5%	$63.6M-13.1%	$48.6M-33.7%	$49.6M-20.4%
Current Liabilities	$40.6M-29.5%	$52.0M-17.1%	$54.8M+14.2%	$56.7M+16.1%	$57.6M-1.2%	$62.8M-13.0%	$48.0M-33.8%	$48.8M-20.3%
Non-Current Liabilities	$175K-74.2%	$217K-72.8%	$430K-34.0%	$554K-27.9%	$677K-23.3%	$798K-19.8%	$652K-26.7%	$768K-28.9%
Total Equity	$23.0M-55.4%	$28.9M-66.0%	$32.8M-65.9%	$43.1M-55.3%	$51.5M-44.9%	$85.1M-12.0%	$96.2M-3.9%	$96.4M-3.9%
Retained Earnings	$3.1M-90.4%	$9.3M-86.1%	$13.3M-83.0%	$23.9M-69.7%	$32.4M-57.7%	$66.5M-7.0%	$78.2M+2.1%	$78.9M+0.4%

Not reported in any period shown, so not listed: Long-Term Debt.

PETS Cash Flow Statement

PETS quarterly cash flow statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$23.8M	-$28.4M-701.8%	$4.7M+9.3%	$4.3M-84.5%	$27.8M+50.3%	$18.5M-53.8%	$40.1M+3.2%	$38.8M-13.9%	$45.1M+20.8%	$37.4M-20.8%	$47.2M+124.2%	$21.1M-34.3%	$32.0M+137.3%	$13.5M+1.6%	$13.3M-34.8%	$20.4M
Depreciation & Amortization	N/A	$9.4M+33.4%	$7.0M-0.2%	$7.1M+99.0%	$3.5M+29.5%	$2.7M+12.8%	$2.4M+7.5%	$2.3M+1.4%	$2.2M+4.7%	$2.1M+55.3%	$1.4M+77.8%	$770K+16.7%	$660K-23.9%	$867K-20.5%	$1.1M-22.7%	$1.4M
Stock-Based Compensation	N/A	$1.4Mn/m	-$6.6M-195.9%	$6.9M+3.8%	$6.6M+45.5%	$4.5M+37.6%	$3.3M+17.2%	$2.8M-8.9%	$3.1M+20.3%	$2.6M+33.1%	$1.9M+20.0%	$1.6M+8.8%	$1.5M+0.1%	$1.5M-23.9%	$1.9M-13.5%	$2.2M
Capital Expenditures	$4.0M	$4.6M-9.7%	$5.1M+13.3%	$4.5M-14.2%	$5.3M+200.2%	$1.8M-28.0%	$2.4M+5.2%	$2.3M+272.7%	$620K-11.8%	$703K-93.4%	$10.6M-47.3%	$20.1M+2092.8%	$918K+1940.0%	$45K-92.8%	$626K-11.2%	$705K
Free Cash Flow	-$27.8M	-$33.0Mn/m	-$395Kn/m	-$194K-100.9%	$22.5M+34.6%	$16.7M-55.5%	$37.6M+3.0%	$36.5M-17.9%	$44.5M+21.4%	$36.7M+0.2%	$36.6M+3865.3%	$923K-97.0%	$31.1M+131.2%	$13.5M+6.3%	$12.7M-35.7%	$19.7M
Investing Cash Flow	-$4.0M	-$4.6Mn/m	-$5.1Mn/m	-$40.7Mn/m	-$10.3Mn/m	-$1.8Mn/m	-$2.4Mn/m	-$2.3Mn/m	-$620Kn/m	-$703Kn/m	-$10.6Mn/m	-$4.5M	N/A	N/A	N/A	N/A
Financing Cash Flow	-$274K	-$299Kn/m	-$181Kn/m	-$12.4Mn/m	-$24.5Mn/m	-$24.4Mn/m	-$22.7Mn/m	-$33.3Mn/m	-$21.9Mn/m	-$17.5Mn/m	-$15.5Mn/m	-$14.5M	N/A	N/A	N/A	N/A
Dividends Paid	N/A	$21K-88.4%	$181K-98.5%	$12.4M-49.3%	$24.5M+0.6%	$24.4M+7.5%	$22.7M+4.1%	$21.8M-0.6%	$21.9M+25.5%	$17.5M+12.6%	$15.5M+5.6%	$14.7M+6.4%	$13.8M+3.6%	$13.3M-58.3%	$32.0M+191.6%	$11.0M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0n/m	$0-100.0%	$11.5Mn/m	$0	N/A	N/A	N/A	N/A	N/A	$3.9M-83.7%	$23.7M

Metric	Q1'2710-Q	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	-$7.7Mn/m	-$4.7M-167.7%	-$9.2Mn/m	-$2.2M-129.4%	-$12.3Mn/m	$7.0M-1.6%	-$1.2Mn/m	$7.4Mn/m
Depreciation & Amortization	$2.1M-5.9%	$2.4M+17.0%	$2.4M+51.3%	$2.3M+37.4%	$2.3M+32.7%	$2.1M+9.4%	$1.6M-10.4%	$1.7M-3.2%
Stock-Based Compensation	$198K-66.5%	N/A	$300K-40.0%	$200K-66.7%	$591Kn/m	N/A	$500K	$600K
Capital Expenditures	$641K-50.4%	$720K-69.8%	-$21K-97.3%	$2.6M+107.4%	$1.3M+89.2%	$2.4M+90.9%	$777K-30.8%	$1.3M+28.6%
Free Cash Flow	-$8.3Mn/m	-$5.5M-218.2%	-$9.2Mn/m	-$4.8M-178.3%	-$13.6Mn/m	$4.6M-21.3%	-$1.9Mn/m	$6.1Mn/m
Investing Cash Flow	-$641Kn/m	-$720Kn/m	$21Kn/m	-$2.6Mn/m	-$1.3Mn/m	-$2.4Mn/m	-$777Kn/m	-$1.3Mn/m
Financing Cash Flow	-$5Kn/m	-$38Kn/m	$0n/m	-$231Kn/m	-$30Kn/m	-$5Kn/m	-$1Kn/m	-$71Kn/m
Dividends Paid	$0-100.0%	N/A	$1K0.0%	$22K-69.0%	$1K-99.0%	$5K-72.2%	$1K-93.3%	$71K-98.9%

Not reported in any period shown, so not listed: Share Buybacks.

PETS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PETS quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	28.1%-2.4pp	30.5%-0.5pp	30.9%0.0pp	30.9%+2.6pp	28.3%+0.5pp	27.8%-0.8pp	28.6%-5.0pp	33.6%-2.1pp	35.7%+3.9pp	31.8%-0.7pp	32.5%-0.7pp	33.3%0.0pp	33.3%-0.6pp	33.9%+0.2pp	33.7%
Operating Margin	-32.8%-32.1pp	-0.7%+2.3pp	-3.0%-5.4pp	2.4%-6.5pp	8.9%-1.1pp	10.1%-0.8pp	10.9%-5.4pp	16.3%-2.8pp	19.0%+4.0pp	15.0%+1.2pp	13.8%+1.8pp	12.0%-0.1pp	12.1%+0.2pp	11.8%+0.9pp	10.9%
Net Margin	-32.0%-29.2pp	-2.8%0.0pp	-2.7%-4.8pp	2.1%-4.8pp	6.9%-1.0pp	7.9%-1.2pp	9.1%-4.2pp	13.3%-0.3pp	13.6%+4.1pp	9.6%+0.8pp	8.8%+1.1pp	7.6%-0.1pp	7.7%+0.2pp	7.5%+0.5pp	7.0%
Return on Equity	-198.0%-190.6pp	-7.4%+0.4pp	-7.7%-12.4pp	4.7%-10.5pp	15.2%-4.0pp	19.1%-2.3pp	21.5%-6.5pp	28.0%-4.2pp	32.2%+6.7pp	25.5%+0.8pp	24.7%+1.6pp	23.1%-2.5pp	25.6%-1.2pp	26.8%+6.3pp	20.5%
Return on Assets	-70.6%-66.3pp	-4.2%+0.2pp	-4.4%-7.5pp	3.1%-7.3pp	10.4%-2.3pp	12.8%-3.9pp	16.6%-7.8pp	24.4%-3.2pp	27.7%+6.5pp	21.1%-1.7pp	22.8%+1.7pp	21.1%-1.9pp	22.9%-0.5pp	23.5%+5.2pp	18.3%
Current Ratio	0.84-0.4x	1.260.0x	1.30-1.0x	2.27-0.4x	2.68-0.9x	3.59-1.7x	5.30-1.5x	6.79+1.0x	5.81+1.4x	4.46-5.1x	9.55-1.2x	10.73+1.6x	9.17+1.5x	7.64-1.7x	9.33
Liabilities-to-Equity	1.81+1.1x	0.750.0x	0.76+0.2x	0.52+0.1x	0.46+0.1x	0.37+0.2x	0.21+0.1x	0.150.0x	0.170.0x	0.21+0.1x	0.090.0x	0.100.0x	0.120.0x	0.140.0x	0.12
Asset Turnover	2.20+0.7x	1.53-0.1x	1.61+0.1x	1.480.0x	1.52-0.1x	1.62-0.2x	1.830.0x	1.84-0.2x	2.03-0.2x	2.21-0.4x	2.60-0.2x	2.77-0.2x	2.98-0.1x	3.11+0.5x	2.62
FCF Margin	-18.4%-18.3pp	-0.2%-0.1pp	-0.1%-9.2pp	9.1%+3.0pp	6.2%-6.3pp	12.4%-0.5pp	12.9%-2.8pp	15.7%+2.3pp	13.4%-1.3pp	14.7%+14.3pp	0.4%-13.2pp	13.6%+7.8pp	5.8%+0.2pp	5.6%-2.7pp	8.3%

Metric	Q1'2710-Q	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Gross Margin	27.6%-0.5pp	32.6%+2.6pp	23.3%-7.8pp	28.0%-4.4pp	28.1%-0.6pp	29.9%+0.6pp	31.0%+0.5pp	32.3%+1.7pp
Operating Margin	-15.2%+51.5pp	-13.3%-1.4pp	-25.8%-24.9pp	-18.9%-19.8pp	-66.7%-73.3pp	-11.9%-6.0pp	-0.9%+4.0pp	0.9%-0.3pp
Net Margin	-15.0%+51.8pp	-9.5%+13.5pp	-25.9%-24.6pp	-19.2%-23.2pp	-66.7%-72.4pp	-22.9%-15.2pp	-1.4%+1.8pp	4.0%+3.0pp
Return on Equity	-26.7%+39.5pp	-14.0%-0.4pp	-32.2%-31.5pp	-19.8%-22.2pp	-66.3%-70.3pp	-13.7%-8.5pp	-0.7%+1.3pp	2.4%+1.7pp
Return on Assets	-9.6%+21.5pp	-5.0%+2.8pp	-12.0%-11.5pp	-8.5%-10.1pp	-31.1%-33.6pp	-7.8%-4.9pp	-0.5%+0.7pp	1.6%+1.1pp
Current Ratio	0.68-0.5x	0.84-0.4x	0.89-0.5x	1.05-0.4x	1.18-0.2x	1.260.0x	1.43+0.1x	1.45+0.1x
Liabilities-to-Equity	1.77+0.6x	1.81+1.1x	1.68+1.2x	1.33+0.8x	1.13+0.5x	0.750.0x	0.51-0.2x	0.51-0.1x
Asset Turnover	0.64+0.2x	0.53+0.2x	0.46+0.1x	0.440.0x	0.470.0x	0.340.0x	0.360.0x	0.400.0x
FCF Margin	-20.3%+6.2pp	-12.8%-21.9pp	-22.7%-18.9pp	-10.8%-21.4pp	-26.5%-12.6pp	9.1%+0.1pp	-3.7%+2.1pp	10.5%+13.1pp

Not reported in any period shown, so not listed: Debt-to-Equity.

Note: The current ratio is below 1.0 (0.84), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
PetMed Express, Inc. PETS	FY2026	$179.0M	-$57.3M	-32.0%	$25.6M	41/100
High Tide Inc. HITI	FY2025	$424.0M	-$36.2M	-8.5%	$230.9M	49/100
Scienture Holdings, Inc. SCNX	FY2025	$432K	-$41.5M	N/A	$4.8M	—
Cellyan Biotechnology Co., Ltd HKPD	FY2026	$13.4M	-$1.1M	-8.5%	$5.4M	44/100

Where PetMed Express, Inc. Ranks

Frequently Asked Questions

What is PetMed Express, Inc.'s annual revenue?

PetMed Express, Inc. (PETS) reported $179.0M in total revenue for fiscal year 2026. This represents a -21.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is PetMed Express, Inc.'s revenue growing?

PetMed Express, Inc. (PETS) revenue declined by 21.1% year-over-year, from $227.0M to $179.0M in fiscal year 2026.

Is PetMed Express, Inc. profitable?

No, PetMed Express, Inc. (PETS) reported a net loss of $29.3M over the trailing 12 months to June 30, 2026. In fiscal year 2026 it reported a net loss of $57.3M, with a net profit margin of -32.0%.

What is PetMed Express, Inc.'s EBITDA?

PetMed Express, Inc. (PETS) had EBITDA of -$49.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is PetMed Express, Inc.'s gross margin?

PetMed Express, Inc. (PETS) had a gross margin of 28.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is PetMed Express, Inc.'s operating margin?

PetMed Express, Inc. (PETS) had an operating margin of -32.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is PetMed Express, Inc.'s net profit margin?

PetMed Express, Inc. (PETS) had a net profit margin of -32.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is PetMed Express, Inc.'s return on equity (ROE)?

PetMed Express, Inc. (PETS) has a return on equity of -198.0% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is PetMed Express, Inc.'s free cash flow?

PetMed Express, Inc. (PETS) recorded an outflow of $33.0M in free cash flow during fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is PetMed Express, Inc.'s operating cash flow?

PetMed Express, Inc. (PETS) recorded an outflow of $28.4M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are PetMed Express, Inc.'s total assets?

PetMed Express, Inc. (PETS) had $81.2M in total assets as of fiscal year 2026, including both current and long-term assets.

What are PetMed Express, Inc.'s capital expenditures?

PetMed Express, Inc. (PETS) invested $4.6M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How many shares does PetMed Express, Inc. have outstanding?

PetMed Express, Inc. (PETS) had 21M shares outstanding as of fiscal year 2026.

What is PetMed Express, Inc.'s current ratio?

PetMed Express, Inc. (PETS) had a current ratio of 0.84 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.

What is PetMed Express, Inc.'s liabilities-to-equity ratio?

PetMed Express, Inc. (PETS) had a liabilities-to-equity ratio of 1.81 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.

What is PetMed Express, Inc.'s return on assets (ROA)?

PetMed Express, Inc. (PETS) had a return on assets of -70.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is PetMed Express, Inc.'s P/E ratio?

PetMed Express, Inc. (PETS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $25.6M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is PetMed Express, Inc.'s price-to-sales ratio?

PetMed Express, Inc. (PETS) trades at 0.2x sales, its market capitalization divided by $168.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $25.6M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does PetMed Express, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, PetMed Express, Inc. (PETS) held $21.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $28.4M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is PetMed Express, Inc.'s Altman Z-Score?

PetMed Express, Inc. (PETS) has an Altman Z-Score of 0.15, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is PetMed Express, Inc.'s Piotroski F-Score?

PetMed Express, Inc. (PETS) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are PetMed Express, Inc.'s earnings high quality?

PetMed Express, Inc. (PETS) reported a net loss of $57.3M while operations used $28.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is PetMed Express, Inc.?

PetMed Express, Inc. (PETS) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For PetMed Express, Inc. it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.